Novartis exits a BioArctic deal worth up to $802m
The Swiss drugmaker ends a blood-brain barrier partnership, and BioArctic says the platform itself isn’t the problem. BioArctic’s news landed at 9:30 pm CET on Monday, 2 November, and by the time Stockholm opened the next morning, the damage showed. Shares in the Swedish biotech fell more than 7% in
<p>The Swiss drugmaker ends a blood-brain barrier partnership, and BioArctic says the platform itself isn’t the problem. BioArctic’s news landed at 9:30 pm CET on Monday, 2 November, and by the time Stockholm opened the next morning, the damage showed. Shares in the Swedish biotech fell more than 7% in</p>